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ABSTRACT
Background
The United States (US) Food and Drug Administration (FDA) approves new drugs based on
sponsor-submitted clinical trials. The publication status of these trials in the medical literature
and factors associated with publication have not been evaluated. We sought to determine the
proportion of trials submitted to the FDA in support of newly approved drugs that are
published in biomedical journals that a typical clinician, consumer, or policy maker living in the
US would reasonably search.
Methods and Findings
We conducted a cohort study of trials supporting new drugs approved between 1998 and
2000, as described in FDA medical and statistical review documents and the FDA approved
drug label. We determined publication status and time from approval to full publication in the
medical literature at 2 and 5 y by searching PubMed and other databases through 01 August
2006. We then evaluated trial characteristics associated with publication. We identified 909
trials supporting 90 approved drugs in the FDA reviews, of which 43% (394/909) were
published. Among the subset of trials described in the FDA-approved drug label and classified
as ‘‘pivotal trials’’ for our analysis, 76% (257/340) were published. In multivariable logistic
regression for all trials 5 y postapproval, likelihood of publication correlated with statistically
significant results (odds ratio [OR] 3.03, 95% confidence interval [CI] 1.78–5.17); larger sample
sizes (OR 1.33 per 2-fold increase in sample size, 95% CI 1.17–1.52); and pivotal status (OR 5.31,
95% CI 3.30–8.55). In multivariable logistic regression for only the pivotal trials 5 y postapproval,
likelihood of publication correlated with statistically significant results (OR 2.96, 95% CI 1.24–
7.06) and larger sample sizes (OR 1.47 per 2-fold increase in sample size, 95% CI 1.15–1.88).
Statistically significant results and larger sample sizes were also predictive of publication at 2 y
postapproval and in multivariable Cox proportional models for all trials and the subset of
pivotal trials.
Conclusions
Over half of all supporting trials for FDA-approved drugs remained unpublished   5 y after
approval. Pivotal trials and trials with statistically significant results and larger sample sizes are
more likely to be published. Selective reporting of trial results exists for commonly marketed
drugs. Our data provide a baseline for evaluating publication bias as the new FDA
Amendments Act comes into force mandating basic results reporting of clinical trials.
The Editors’ Summary of this article follows the references.
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In the United States, the Food and Drug Administration
(FDA) approves new drug products for sale and marketing
based on results from clinical investigations that demonstrate
the safety and efﬁcacy of a drug for a proposed indication.
Sponsors of a drug (e.g., companies, research institutions, or
government) seek approval by submitting a new drug
application (NDA) [1] to the FDA, which must include
documentation and analyses of all animal and human trial
data, as well as information about the ingredients, clinical
pharmacology, manufacturing, processing, and packaging of
the drug. The FDA relies on sponsors to submit all data,
including complete protocols, protocol revisions, and data
from failed trials in the NDA. The NDA is then reviewed by
clinicians, statisticians, chemists, clinical pharmacologists,
and other relevant scientiﬁc and regulatory disciplines within
the FDA to conﬁrm and validate the sponsor’s conclusion
that a drug is safe and effective.
For drugs that receive FDA approval, public disclosure of
trial results may occur through a variety of sources. The FDA
discloses a Summary Basis of Approval document that
contains summaries and evaluations of clinical data and
statistical analyses performed by FDA medical ofﬁcers during
the approval process [2]. However, these summaries contain
only selected results from the clinical trials [1], and data
deemed conﬁdential or information considered commercial
under Exemption 4 of the Freedom of Information Act may
be redacted [3]. The drug label or package insert also provides
a summary of clinical studies but often in less detail than the
Summary Basis of Approval. Publication in the peer-reviewed
medical literature is the main channel by which trial results
are publicly disclosed and communicated to clinicians. The
complete and accurate reporting of clinical trial results is
crucial to ensuring an unbiased evidence base for advancing
science and facilitating informed clinical decision-making [4],
and has been considered an ethical obligation [5]. However,
there was no requirement until very recently that trial results
be published or otherwise made public for FDA-approved
and marketed drugs.
A string of recent controversies concerning the suppres-
sion of safety risks of rosiglitazone [6], paroxetine [7], and
rofecoxib [8,9] has drawn public attention to the limited and
incomplete public access to clinical trial results on FDA-
approved drugs [10] and has resulted in a concerted effort to
achieve improved compliance with trial registration and
greater disclosure of trial results [11–13].
In response to these concerns, the US recently mandated in
the FDA Amendments Act 2007 (Public Law 110–85) that all
trials supporting FDA-approved drugs and devices must be
registered at inception and have their ‘‘basic results’’ publicly
posted by the National Institutes of Health. The basic results
to be disclosed include the demographics of the study
participants, the number of participants who dropped out
or were excluded from analysis, and the numeric and
statistical test results of all primary and secondary outcomes
declared at initial trial registration.
For the foreseeable future, however, the detailed informa-
tion needed for full appraisal of a trial’s evidence is likely to
be available only in journal publications. This information
includes protocol, protocol deviation, and conﬂicts of
interest information, as well as additional analyses beyond
the primary and secondary outcomes. The availability of basic
results on ClinicalTrials.gov (http://www.clinicaltrials.gov/) will
therefore complement, but not supplant, the medical
literature’s continuing role as the dominant channel of
communication to clinicians and the public, even after the
imposition of mandatory basic results reporting.
Previous research has documented the problem of pub-
lication bias and incomplete or selective reporting of trials
submitted to licensing authorities in Sweden [14,15], Finland
[14], and the US [10,16]. For example, among trials of
antidepressants submitted to the FDA [16] or the Swedish
drug regulatory authority [15], efﬁcacy trials reporting
positive results and larger effect sizes were more likely to
be published. These analyses were limited to one drug class,
speciﬁcally, antidepressants. Therefore, we evaluated the
publication status of trials submitted to the FDA for a wide
variety of approved drugs and identiﬁed factors associated
with publication.
Methods
Identification of Clinical Trials
We identiﬁed all drugs approved by the FDA between
January 1998 and December 2000 at the Center for Drug
Evaluation and Research Web site, available at http://www.fda.
gov/cder/da/da.htm. We included only new drugs classiﬁed as
‘‘new molecular entities,’’ which are drug products that have
never been previously approved by the FDA for any
indication, hereafter referred to as ‘‘new drug.’’ For each
new drug, we retrieved the FDA Summary Basis for Approval
and evaluated the medical and statistical review documents to
identify clinical trials submitted by the sponsor. These review
documents are available at http://www.accessdata.fda.gov/
scripts/cder/drugsatfda/index.cfm for all new drugs approved
since 1998.
Classification of Clinical Trials
Phase I trials are often small studies designed to provide
supporting information about a drug’s pharmacokinetic
parameters, dosing schedule, common side effects, tolerabil-
ity, and toxicity, but are limited by design or other factors in
their ability to demonstrate efﬁcacy. Phase II and III trials are
often larger studies designed to provide evidence on the
overall risks and beneﬁts of a drug. The phase of a trial was
often not reported in the FDA documents. Sponsors and the
FDA frequently categorize certain trials as ‘‘pivotal.’’ These
are trials that demonstrate the efﬁcacy and safety of a drug
for its proposed indication and provide the most useful
information for clinical decision-making. Pivotal trials are
typically Phase II or III trials, but there is no formal deﬁnition
of a pivotal trial. In practice, trials that are reported in the
‘‘clinical studies’’ or ‘‘clinical efﬁcacy’’ section of the FDA-
approved drug label are considered pivotal. We used this
scheme to categorize trials as ‘‘pivotal’’ or ‘‘nonpivotal.’’ We
obtained the product label at the time of FDA approval for
each new drug, or the next available product label if the
initial product label was not available, at http://www.fda.gov/
cder/approval/index.htm. Trials described in the summary
documents for each drug approval that were also described in
the ‘‘clinical studies’’ section of the corresponding drug label
were categorized as pivotal. All other trials were categorized
as nonpivotal.
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Publication of New Drug Clinical TrialsData Extraction
For each submitted trial, we recorded the following
characteristics when available in the FDA documents: drug
name (generic and trade), the number and location of study
sites, the name of the principal investigator, the number of
study participants, dosage and evaluation schedules, sample
size, statistical signiﬁcance of the primary outcome (p , 0.05
or conﬁdence interval [CI] excluding no difference; or if the
study was an equivalency study, p . 0.05 or CI including no
difference or a CI excluding the prespeciﬁed difference
described in the trial). Nonsigniﬁcant or null results are
deﬁned as p . 0.05 or CI including no difference; or if the
study was an equivalency study, p , 0.05 or CI excluding no
difference or a CI including the prespeciﬁed differences
described in the trial. We also recorded whether the trial was
randomized or double blinded as reported by the sponsor in
the FDA documents.
Search Strategy and Publication Matching
We systematically searched common databases of biomed-
ical journals that a typical clinician, consumer, or policy
maker living in the US would reasonably search. These
databases were PubMed, Cochrane Library, and the Cumu-
lative Index for Nursing and Allied Health Literature
(CINAHL). First, we electronically searched PubMed to match
each trial identiﬁed in the FDA review documents to
publications in the medical literature. We initially used the
new drug’s generic name and limited the search to
Publication Type: Clinical Trial. All English-language retriev-
als were reviewed in abstract or full-text form. Trials
identiﬁed in the FDA reviews were matched to a publication
based on the following characteristics: drug name, sample
size, dosing schedules, number and location of study centers,
primary outcome measures, and statistical signiﬁcance or
estimated effect of the primary outcome results.
Only original research reports in full journal articles were
counted as matching publications; abstracts or review articles
were not considered matches, as these types of articles by
deﬁnition contain incomplete descriptions of a trial’s
methods and results. For remaining trials that were not
matched to a publication, we searched PubMed again without
publication type limits using a variety of keywords (e.g.,
generic drug name; names of other drugs in the trial; disease/
condition studied; outcomes measured; and trial character-
istics such as ‘‘cross over’’, ‘‘randomize’’, ‘‘blind’’, ‘‘washout’’,
‘‘placebo’’, ‘‘pharmacokinetics’’,a n d‘‘bioavailability’’). If
trials remained unmatched to a publication in PubMed after
this more comprehensive search, we searched the entire
Cochrane Library and CINAHL databases without limits
using the similar keyword strategy described above. We also
reviewed The Medical Letter (http://www.medletter.com/) for
additional trial publications. For each trial, we veriﬁed
statistical signiﬁcance of primary results, randomization,
double blinding, and sample size by reviewing the publica-
tion. We completed our literature search on 01 August 2006,
which yields a follow-up period ranging between 5.5 to 8.5 y
from the time of a new drug’s approval (January 1998 to
December 2000).
Statistical Analysis
The main outcome measures were time from FDA approval
to publication of a full report, and whether a report was
published by 2 or 5 y after approval. We analyzed publication
at 2 y because pending Congressional legislation is consider-
ing mandating results reporting by 2 y after drug approval.
Trials that were not published were censored as of 01 August
2006.
To control for multiple variables simultaneously, we
carried out multivariate mixed effects logistic regression
analysis and calculated odds ratios at 2 and 5 y after approval.
All models were adjusted for clustering by drug (treated as a
random effect). Predictors assessed in both univariate and
multivariable analyses included statistical signiﬁcance of the
primary results, double blinding, randomization, sample size
(dichotomized at the median size of   135 or . 135, or log-
transformed to each 2-fold increase in sample size), study
type (pivotal or not), and company size. Companies with
annual revenues greater than $3 billion, and/or annual
research and development expenditures greater than $500
million in 2004, were classiﬁed as large companies, and
generally represented the top 30 pharmaceutical and
biotechnology companies in the world [17]. Month zero was
deﬁned as the month of FDA approval as stated in the FDA
documents. The publication month was the month of the
journal issue in which the trial appeared. Trials published
before their FDA approval date were analyzed as published at
time zero. In cases of duplicate publication (those reporting
the same ﬁndings and results from the same trial, study
population, intervention, and measured outcomes), we
included only the earliest publication in all analyses. We
chose variables for inclusion in multivariable models using
forward stepwise selection with p , 0.05 required for entry
and retention.
Our primary analysis was logistic regression analyses on all
supporting trials (n ¼ 909 trials). Our secondary analysis was
on the subset of trials classiﬁed as pivotal (n¼340 trials). Data
were analyzed with SAS software (version 9.1, SAS Institute).
Results
All Supporting Trials
We identiﬁed 90 FDA-approved new drugs between
January 1998 and December 2000. Eighty-nine (99%) of the
applications were submitted by a pharmaceutical company;
one application was submitted by the US Army Medical
Research and Material Command. Eighty-eight drugs were
available by prescription only and two had over-the-counter
marketing status. Seven prescription drug products were
discontinued after initial FDA approval. We were able to
identify a total of 909 trials with sufﬁcient description in the
FDA review documents supporting these 90 new drugs. Table
1 describes the trials’ characteristics. We matched 394 of
these trials (43%) to publications in the medical literature
(Figure 1): 393 to publications in PubMed, the Cochrane
Library, or the CINAHL database, and one to a publication
cited by The Medical Letter but not indexed by the searched
databases. The remaining 515 trials (57%) could not be
matched to any publication. The proportion of trials
published per new drug ranged from 0% to 100%, with an
average of 55% of supporting trials published per new drug
(Table S1). One of the 90 new drugs, an antibiotic, had none
of its supporting trials published. Duplicate publications were
seen in six trials: ﬁve trials had results published twice and
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matched publications.
In univariate analyses of all supporting trials, trials with
statistically signiﬁcant results, larger sample sizes, double
blinding, randomization, and trials that were pivotal were
more likely to be published by 2 and 5 y after FDA approval
(Table 2). Company size did not appear to be associated with
publication. When controlling for all of these factors
simultaneously in multivariable analyses, statistically signiﬁ-
cant results, larger sample sizes, and pivotal status continued
to be strong predictors of publication at 2 and 5 y after FDA
approval (Table 3). Adding an interaction of statistically
signiﬁcant results and sample size estimated the effect of
sample size to be smaller for studies with statistically
signiﬁcant results by a factor of 0.81 (p ¼ 0.19) at 2 y and
0.79 (p ¼ 0.14) at 5 y. Because statistical signiﬁcance was
missing for many studies, we also ﬁt models like those in
Tables 2 and 3, but with ‘‘unknown’’ statistical signiﬁcance
counted as a third possible category. This permitted inclusion
of 883 trials, but produced no qualitative changes in the
results. Trials with unknown statistical signiﬁcance were
estimated to be less likely to be published than trials with
nonsigniﬁcant results at 2 y (OR 0.71, p ¼ 0.28) and 5 y (OR
0.59, p¼0.067) with a nearly unchanged estimate of the effect
of statistical signiﬁcance (OR 2.53, p¼0.001 at 2 y, OR 3.06, p
, 0.001 at 5 y). Results from Cox proportional hazards
modeling with a shared gamma frailty were qualitatively
similar to the random effects logistic regression results and so
are not shown.
Figure 2 shows the yearly number and cumulative
proportion of trials published relative to the time of FDA
approval. Thirty-two percent (128/394) of the publications
occurred prior to the relevant new drug’s FDA approval and
92% (364/394) were published within 3 y of FDA approval.
Among published trials reporting the statistical signiﬁcance
of their primary outcome (n ¼ 337), the median time to
publication from FDA approval for trials with statistically
signiﬁcant results was 0.77 y (range 0–4.41 y, n¼285) and 0.73
y for trials without statistically signiﬁcant results (range 0–
3.84 y, n ¼ 52).
Pivotal Trials
Of the 909 trials, 340 (37%) were identiﬁed as pivotal, of
which 257 (76%) were published (Figure 1). The predictors of
publication for pivotal trials were similar to those for all
supporting trials in univariate (Table 2) and multivariate
analyses (Table 3). Interaction of statistically signiﬁcant
results and sample size was similar to that for all trials, with
the effect of sample size estimated to be smaller for studies
with statistically signiﬁcant results by a factor of 0.82 (p ¼
0.54) at 2 y and 0.83 (p ¼ 0.54) at 5 y. Like the analysis of all
trials, counting unknown statistical signiﬁcance as a valid
third category permitted inclusion of more trials (n¼339) but
produced no qualitative changes in results. Figure 3 shows the
yearly number and cumulative proportion of pivotal trials
published relative to the time of FDA approval. Thirty-two
percent (82/257) of the publications occurred prior to the
relevant drug’s FDA approval and 95% (245/257) were
published within 3 y after FDA approval.
Discussion
Our study evaluated the publication of 909 clinical trials
identiﬁed in FDA medical and statistical review documents in
support of 90 new drug products approved between 1998 and
2000. We found that after a minimum of 5.5 y of follow-up
after FDA approval, we identiﬁed publications from 43% of
Table 1. Characteristics and Publication Rates of Trials Submitted for FDA Approval in 1998–2000
Characteristic Category All Trials (n ¼ 909) Pivotal Trials Only (n ¼ 340)
Total n (%
a) Published n (%
b) Total n (%
a) Published n (%
b)
Total — 909 (100) 394 (43) 340 (100) 257 (76)
Statistical significance of results
c Not statistically significant 144 (25) 52 (36) 50 (17) 33 (66)
Statistically significant 432 (75) 285 (66) 239 (83) 199 (83)
Randomization
d No 98 (14) 38 (39) 32 (10) 24 (75)
Yes 602 (86) 329 (55) 281 (90) 217 (77)
Double blinding
e No 293 (37) 96 (33) 80 (25) 60 (75)
Yes 504 (63) 270 (54) 241 (75) 184 (76)
Sample size
f  135 443 (50) 120 (27) 76 (22) 48 (63)
.135 440 (50) 273 (62) 263 (78) 209 (79)
Company size
g Small 342 (38) 143 (42) 138 (41) 103 (75)
Large 567 (62) 251 (44) 202 (59) 154 (76)
Study type
h Nonpivotal 569 (63) 137 (24) N/A N/A
Pivotal 340 (37) 257 (76) N/A N/A
aPercentage of grand total.
bPercentage of row category that were published as of 01 August 2006.
cStatistically significant results were defined as p , 0.05; 95% CI for difference excluding 0; 95% CI for ratio excluding 1; or if the study was an equivalency study, p . 0.05 or CI including
no difference or a CI excluding the prespecified difference described in the trial). 305 trials did not report the statistical significance of their results, and 28 trials reported results that were
not applicable to the primary outcome.
dWe could not determine whether the trial was randomized or not for 209 trials.
eWe could not determine whether the trial was double blinded or not for 112 trials.
fSample size was dichotomized at the median of 135. 26 trials did not report a sample size.
gCompanies with annual revenues . $3 billion, and/or annual research and development expenditures greater than $500 million in 2004 were classified as large companies, and generally
represented the top 30 pharmaceutical and biotechnology companies in the world [17].
hTrials reported in the ‘‘clinical studies’’ or ‘‘clinical efficacy’’ section of the FDA-approved drug label were considered pivotal.
doi:10.1371/journal.pmed.0050191.t001
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are more clinically informative than nonpivotal trials, we
found publications from 76% of the trials. For one of the 90
approved new drugs, we could not ﬁnd any published
supporting trial. We also found strong evidence of publica-
tion bias: trials with statistically signiﬁcant results were more
likely to be published than trials with nonsigniﬁcant results,
as were trials with larger sample sizes. There was a weak
suggestion that the effect of sample size might be less among
trials with statistically signiﬁcant ﬁndings, but p-values for
such interactions did not reach statistical signiﬁcance. Our
study therefore shows that previous ﬁndings of publication
bias of trials supporting the regulatory applications of
selected drug classes (e.g., antidepressants) [10,14–16] are
broadly true across a diverse group of drug classes.
Publication bias may lead to an inappropriately favorable
record in the medical literature of a drug’s true risk/beneﬁt
proﬁle relative to other standard therapies, and may thus lead
to preferential prescribing of newer and more-expensive
treatments. We could not test whether similar publication
bias exists for trials supporting unsuccessful new drug
applications because adequate information about these
applications was unavailable from the FDA or other govern-
ment or commercial sources.
We also found the reporting of clinical trials in the FDA
review documents and drug labels to be variable in detail and
content, and not an adequate substitute for full publication
in the medical literature. For example, reporting ranged from
detailed descriptions of a trial’s study design, intervention,
patient population, statistical analyses, adverse events, pri-
mary outcomes, and other results, to brief statements that
only summarized a trial’s primary outcome. We also noted
sections of redacted information in the FDA review docu-
ments. Neither the FDA review documents nor the drug labels
followed a standard format for reporting a trial’s method-
ology and results. Use of guidelines such as the revised
CONSORT (Consolidated Standards of Reporting Trials) [18]
may help to improve the quality and completeness of trial
reporting in FDA review documents as others have proposed
[19].
Our study has several limitations. First, we may have
misclassiﬁed some published trials as being unpublished
because of difﬁculties in matching publications to incomplete
trial descriptions in the FDA documents. Also, we did not
search other databases such as the European EMBASE, nor
did we contact investigators or sponsors to determine
publication status or verify that a trial was not published or
in press. Thus, we are likely to have underestimated the
overall publication rate of these trials. However, we believe
that for clinicians and policy makers, the most relevant
publication rate is not the overall rate but the publication
rate in journals that a typical clinician, consumer, or policy
maker would have access to through a reasonable literature
search. We believe our searches of PubMed, the Cochrane
Figure 1. Flowchart of Publications by Type of Trial Supporting Applications for New Drug Approvals in 1998–2000
1Clinical trials that are adequately designed to demonstrate efficacy of the drug for a proposed indication and reported in the ‘‘clinical studies’’ or
‘‘clinical efficacy’’ section of the FDA approved drug label.
2Time to publication in years counting from the month of FDA approval.
doi:10.1371/journal.pmed.0050191.g001
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Publication of New Drug Clinical TrialsLibrary, and CINAHL reﬂect such a reasonable search. It
would not be reasonable to expect a clinician, consumer, or
policy maker to contact investigators or sponsors to
determine a trial’s publication status.
A second limitation of our study is our follow-up time of
5.5 to 8.5 y after new drug approval may be inadequate.
However, we found that publications occurred almost
exclusively within the ﬁrst 3 y after approval, making it
unlikely that longer follow-up would yield many additional
publications. Third, time-to-publication is ideally counted
from the date of trial completion, but we were unable to
obtain these dates reliably. Moreover, we believe the month of
approval is the most relevant time point when trial results
should be available to the public. Fourth, our study focused
on publications in the medical literature, but some compa-
nies have started making their trial results publicly available
directly on their own Web sites. For example, the pharma-
ceutical industry’s Clinical Study Results Database contains
summaries of ‘‘hypothesis-testing’’ trials completed since
October 2002 for many pharmaceutical products [20]. We
searched this database for the 515 unpublished trials and
found summaries for 22 (4%) of them. The effect of this and
Table 3. Characteristics Associated with Publication of Trials Submitted for FDA Approval in 1998–2000: Multivariable Logistic
Regression
a
Group Characteristic Publication at 2 Years Postapproval Publication at 5 Years Postapproval
Odds Ratio
(95% CI)
p-Value Odds Ratio
(95% CI)
p-Value
All trials (n ¼ 571) Significant results vs. nonsignificant 2.48 (1.43–4.30) 0.002 3.03 (1.78–5.17) ,0.001
Larger sample size
b 1.35 (1.17–1.55) ,0.001 1.33 (1.17–1.52) ,0.001
Pivotal study vs. nonpivotal 4.78 (2.93–7.77) ,0.001 5.31 (3.30–8.55) ,0.001
Pivotal trials only (n ¼ 289) Significant results vs. nonsignificant 2.55 (1.13–5.79) 0.026 2.96 (1.24–7.06) 0.015
Larger sample size
b 1.43 (1.13–1.80) 0.003 1.47 (1.15–1.88) 0.003
aMixed effects logistic regression; approved drug is treated as a random effect.
bOdds ratio associated with each 2-fold increase in sample size.
doi:10.1371/journal.pmed.0050191.t003
Table 2. Characteristics Associated with Publication of Trials Submitted for FDA Approval in 1998–2000: Univariate Logistic
Regression
a
Group Characteristic Category Publication at 2 Years Postapproval Publication at 5 Years Postapproval
Published n/
Total n (%)
OR (95% CI) p-Value Published n/
Total n (%)
OR (95% CI) p-Value
All trials
(n ¼ 909)
Statistical significance
of results (n ¼ 576)
Not statistically
significant
41/144 (29) 1.00 — 52/144 (36) 1.00 —
Statistically
significant
237/432 (55) 3.56 (2.16–5.86) ,0.001 285/432 (66) 4.16 (2.56–6.74) ,0.001
Randomization (n ¼ 700) No 33/98 (34) 1.00 — 38/98 (39) 1.00 —
Yes 271/602 (45) 1.97 (1.13–3.45) 0.018 329/602 (55) 2.17 (1.31–3.58) 0.0029
Double binding (n ¼ 797) No 79/293 (27) 1.00 — 96/293 (33) 1.00 —
Yes 225/504 (45) 3.97 (2.40–6.58) ,0.001 270/504 (54) 3.38 (2.20–5.19) ,0.001
Larger sample size
b (n ¼ 883) — 1.72 (1.54–1.91) ,0.001 — 1.75 (1.58–1.93) ,0.001
Company size (n ¼ 909) Small 117/342 (34) 1.00 — 143/342 (42) 1.00 —
Large 211/567 (37) 1.15 (0.69–1.91) 0.58 251/567 (44) 1.03 (0.66–1.62) 0.90
Study type (n ¼ 909) Nonpivotal 105/569 (19) 1.00 — 137/569 (24) 1.00 —
Pivotal 223/340 (66) 10.82 (7.31–16.01) ,0.001 257/340 (76) 11.40 (7.85–16.55) ,0.001
Pivotal trials only
(n ¼ 340)
Statistical significance
of results (n ¼ 289)
Not statistically
significant
27/50 (54) 1.00 — 33/50 (66) 1.00 —
Statistically
significant
172/239 (72) 2.91 (1.28–6.63) 0.012 199/239 (83) 3.40 (1.43–8.09) 0.0063
Randomization (n ¼ 313) No 23/32 (72) 1.00 — 24/32 (75) 1.00 —
Yes 185/281 (66) 0.83 (0.29–2.33) 0.72 217/281 (77) 1.30 (0.49–3.44) 0.60
Double blinding (n ¼ 321) No 55/80 (69) 1.00 — 60/80 (75) 1.00 —
Yes 157/241 (65) 1.05 (0.50–2.20) 0.89 184/241 (76) 1.36 (0.65–2.87) 0.41
Larger sample size
b
(n ¼ 339)
— 1.40 (1.14–1.70) 0.001 — 1.45 (1.18–1.78) ,0.001
Company size (n ¼ 340) Small 85/138 (62) 1.00 — 103/138 (75) 1.00 —
Large 138/202 (68) 1.31 (0.69–2.50) 0.41 154/202 (76) 1.01 (0.54–1.87) 0.98
aUnivariate logistic regression; approved drug is treated as a random effect. Odds ratio may differ in direction from the direction based only on the raw counts due to the clustering by
approved drug.
bOdds ratio associated with each 2-fold increase in sample size.
doi:10.1371/journal.pmed.0050191.t002
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submitted to the FDA requires further research as the
information reported in these databases may not be peer
reviewed and there is no guarantee that the reporting is
complete for all relevant data. Fifth, we could not determine
the statistical signiﬁcance of the ﬁndings of a substantial
proportion of the studies. We did, however, obtain qualita-
tively similar results when we performed a sensitivity analysis
by counting unknown statistical signiﬁcance as a valid third
category. Finally, our ﬁndings cannot be generalized to any
speciﬁc product, company, institution, organization, or
investigator.
Despite these limitations, our study provides ample
evidence that in the years immediately following FDA
approval that are most relevant to public health, there exists
incomplete and selective publication of trials supporting
approved new drugs. Potential reasons for this publication
bias may include the tendency of investigators and sponsors
to delay or not submit trial reports [21,22], or the motivation
of commercial sponsors to publish positive trials in presti-
gious journals to obtain article reprints for marketing [23].
Bias in editorial decisions toward publishing positive results
is also possible, although there is evidence suggesting that this
is not the case [24,25]. Regardless of the cause, publication
bias harms the public good by impairing the ability of
clinicians and patients to make informed clinical decisions,
and the ability of scientists to design safer and more efﬁcient
trials based on past ﬁndings. Publication bias can thus be
considered a form of scientiﬁc misconduct [5].
Potential Effects of Mandatory Results Reporting on
Publication Bias
As discussed above, the FDA Amendments Act of 2007
mandates basic public results reporting for all trials support-
ing FDA-approved drugs and devices. Our study shows that
this legislation was necessary because current reporting is
marked by pervasive publication bias of positive over
negative trials. Moreover, because published trial reports
are often incomplete [26] and have been shown to selectively
report favorable outcome results [27], the published evidence
supporting FDA-approved drugs may be even more skewed
than our results suggest. By ensuring the reporting of all
predeclared primary and secondary outcomes regardless of
their direction of beneﬁt, the new law should go a long way
toward correcting this skew.
We anticipate that the new law will also speed the
dissemination of trial information. Currently, according to
our data, 40% of the trials that were eventually published
were published more than 1 y postapproval (34% of pivotal
trials). Under the new law, basic results for all trials must be
posted by 1 y after trial completion or approval of the drug or
device. This suggests that for all trials that the sponsor wishes
to publish, the manuscripts will have to be submitted for peer
review before the 1 y postapproval mark if they hope to allay
journal concerns about publishing trials whose primary and
secondary outcome results have already been publicly posted.
Thus, we would expect the time-to-publication curves in
Figures 2 and 3 to shift left.
Paradoxically, however, this new law may increase rather
than decrease publication bias. Might sponsors feel less
compelled to publish equivocal trials because the basic
results will already be in the public domain? Might the time
pressure to submit manuscripts by 1 y postapproval focus
sponsor efforts even more on submitting positive trials and
trials of greatest interest to journals? Might the journals, if
they accept manuscripts of trials with publicly posted results,
change the criteria by which publication importance is
judged, and how might this affect acceptance rates [28]?
When more detailed protocol information must also be
posted on ClinicalTrials.gov, to start no later than October
2010, the effect on publication practices is even harder to
anticipate. Our data document the current degree of
publication bias and provide a baseline for assessing the
evolving publication practices of trials supporting FDA-
Figure 2. Yearly Publications of Trials Supporting Approval of New
Drugs: Publication of Supporting Trials (n ¼ 394/909)
Trials from less than half of the cohort (43%) were published. Of the trials
that were published, 92% were published within 3 y of FDA approval.
Trials could be published prior to or following submission of data to the
FDA.
doi:10.1371/journal.pmed.0050191.g002
Figure 3. Yearly Publications of Trials Supporting Approval of New
Drugs: Publication of Pivotal Trials (n ¼ 257/340)
Of the pivotal trials that were published, 95% were published within 3 y
of FDA approval. Trials could be published prior to or following
submission of data to the FDA.
doi:10.1371/journal.pmed.0050191.g003
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effect.
Supporting Information
Table S1. Number and Publication of Supporting and Pivotal Trials
Per Drug
Number of supporting trials and the proportion published, and the
number of pivotal trials and the proportion published, for each of the
90 drugs analyzed.
Found at doi:10.1371/journal.pmed.0050191.st001 (215 KB DOC).
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Publication of New Drug Clinical TrialsEditors’ Summary
Background. Before a new drug becomes available for the treatment of
a specific human disease, its benefits and harms are carefully studied,
first in the laboratory and in animals, and then in several types of clinical
trials. In the most important of these trials—so-called ‘‘pivotal’’ clinical
trials—the efficacy and safety of the new drug and of a standard
treatment are compared by giving groups of patients the different
treatments and measuring several predefined ‘‘outcomes.’’ These
outcomes indicate whether the new drug is more effective than the
standard treatment and whether it has any other effects on the patients’
health and daily life. All this information is then submitted by the
sponsor of the new drug (usually a pharmaceutical company) to the
government body responsible for drug approval—in the US, this is the
Food and Drug Administration (FDA).
Why Was This Study Done? After a drug receives FDA approval,
information about the clinical trials supporting the FDA’s decision are
included in the FDA ‘‘Summary Basis of Approval’’ and/or on the drug
label. In addition, some clinical trials are described in medical journals.
Ideally, all the clinical information that leads to a drug’s approval should
be publicly available to help clinicians make informed decisions about
how to treat their patients. A full-length publication in a medical journal
is the primary way that clinical trial results are communicated to the
scientific community and the public. Unfortunately, drug sponsors
sometimes publish the results only of trials where their drug performed
well; as a consequence, trials where the drug did no better than the
standard treatment or where it had unwanted side effects remain
unpublished. Publication bias like this provides an inaccurate picture of a
drug’s efficacy and safety relative to other therapies and may lead to
excessive prescribing of newer, more expensive (but not necessarily
more effective) treatments. In this study, the researchers investigate
whether selective trial reporting is common by evaluating the
publication status of trials submitted to the FDA for a wide variety of
approved drugs. They also ask which factors affect a trial’s chances of
publication.
What Did the Researchers Do and Find? The researchers identified 90
drugs approved by the FDA between 1998 and 2000 by searching the
FDA’s Center for Drug Evaluation and Research Web site. From the
Summary Basis of Approval for each drug, they identified 909 clinical
trials undertaken to support these approvals. They then searched the
published medical literature up to mid-2006 to determine if and when
the results of each trial were published. Although 76% of the pivotal
trials had appeared in medical journals, usually within 3 years of FDA
approval, only 43% of all of the submitted trials had been published.
Among all the trials, those with statistically significant results were nearly
twice as likely to have been published as those without statistically
significant results, and pivotal trials were three times more likely to have
been published as nonpivotal trials, 5 years postapproval. In addition, a
larger sample size increased the likelihood of publication. Having
statistically significant results and larger sample sizes also increased
the likelihood of publication of the pivotal trials.
What Do These Findings Mean? Although the search methods used in
this study may have missed some publications, these findings suggest
that more than half the clinical trials undertaken to support drug
approval remain unpublished 5 years or more after FDA approval. They
also reveal selective reporting of results. For example, they show that a
pivotal trial in which the new drug does no better than an old drug is less
likely to be published than one where the new drug is more effective, a
publication bias that could establish an inappropriately favorable record
for the new drug in the medical literature. Importantly, these findings
provide a baseline for monitoring the effects of the FDA Amendments
Act 2007, which was introduced to improve the accuracy and
completeness of drug trial reporting. Under this Act, all trials supporting
FDA-approved drugs must be registered when they start, and the
summary results of all the outcomes declared at trial registration as well
as specific details about the trial protocol must be publicly posted within
a year of drug approval on the US National Institutes of Health clinical
trials site.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050191.
  PLoS Medicine recently published an editorial discussing the FDA
Amendment Act and what it means for medical journals: The PLoS
Medicine Editors (2008) Next Stop, Don’t Block the Doors: Opening Up
Access to Clinical Trials Results. PLoS Med 5(7): e160
  The US Food and Drug Administration provides information about
drug approval in the US for consumers and for health care
professionals; detailed information about the process by which drugs
are approved is on the Web site of the FDA Center for Drug Evaluation
and Research (in English and Spanish)
  ClinicalTrials.gov provides information about the US National Institutes
of Health clinical trial registry, background information about clinical
trials, and a fact sheet detailing the requirements of the FDA
Amendments Act 2007 for trial registration
  The World Health Organization’s International Clinical Trials Registry
Platform is working toward international norms and standards for
reporting the findings of clinical trials
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